Boston Scientific advised physicians about a particular pacemaker in 2005--but then declined to pay the bills for those surgeries that it subsequently received from German health insurers. An EU court ruled on March 5 that the company is liable for those costs, according to Reuters.
During the continued wave of life science M&A, companies are seeking to focus on core competencies. Once again, this trend has resulted in Boston Scientific snatching the medical device assets of a pharma company, this time from Endo International.
Boston Scientific touted its new cleared endoscopic SpyGlass DS Direct Visualization System enabling direct visualization of the biliary tree and pancreatic ducts. With the FDA's 510(k) clearance now in hand, the device can hit the market.
Boston Scientific sat out most rounds of med tech M&A the past few years, but the device giant might be charting a different course in 2015. The company is reportedly close to buying Endo International's AMS medical device unit in a deal estimated at $2 billion.
Bayer is slated to sell its diabetes devices business to Panasonic Healthcare, according to a report from Bloomberg. The move has been years in the making as Bayer works to sell off peripheral businesses to focus on its core profitable ones.
Boston Scientific is forking over $600 million to settle its ongoing breach-of-contract lawsuit with Johnson & Johnson over a failed bidding war for devicemaker Guidant, laying its decade-old courtroom saga to rest.
The market for drug-coated angioplasty balloons to treat peripheral artery disease has been bursting with activity in recent months. Boston Scientific joined the parade today, albeit as a distributor.
U.S. District Judge Joseph Goodwin once again pled for a comprehensive settlement between 7 devicemakers and the plaintiffs in the 70,000 lawsuits they face over potentially dangerous transvaginal mesh.
Shares of Boston Scientific are up slightly on earnings of $87 million on revenues of $1.9 billion in the fourth quarter of 2014, representing a change of 3% year over year.
Industry players are scrambling to differentiate their implantable cardioverter defibrillators that deliver electric shocks to correct abnormal heart rhythms in patients with ventricular tachycardia or fibrillation. Medtronic has touted studies showing that its devices produce fewer unnecessary shocks than the industry norm and are easy to program. Today, it's Boston Scientific's turn.